Loading...
01/11 03:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed sentiment. Financial performance is stable with a cash runway into 2028, but increased expenses and lack of clear guidance on critical studies raise concerns. The Q&A session highlights positive interest from the medical community and strategic planning, yet management's vague responses on potential risks and uncertainties, like orphan drug designation, dampen optimism. Given these factors, the stock price is likely to remain neutral in the short term, with no significant catalysts for a strong movement.
Net Loss $11.8 million for Q3 2025, compared to $13.2 million for Q3 2024, a decrease due to reduced clinical trial work as trials were actively enrolling in the prior year and reported data in the first half of this year. This was partially offset by increased costs related to recently completed Phase I study and personnel expenses.
R&D Expenses $10.1 million for Q3 2025, compared to $11.2 million for Q3 2024, a decrease primarily due to reduced clinical trial work as trials were actively enrolling in the prior year and reported data in the first half of this year. This was partially offset by increased costs related to recently completed Phase I study and personnel expenses.
G&A Expenses $3.8 million for Q3 2025, compared to $2.9 million for Q3 2024, an increase primarily due to higher professional fees and personnel expenses, including costs related to compliance with SOX 404(b) regulations.
Cash and Investments $195 million as of September 30, 2025, providing cash runway into 2028, subject to finalizing the development for each indication.
CORAL trial for chronic cough in IPF: Positive data readouts presented at CHEST conference, showing strong interest from thought leaders and pulmonologists.
RIVER trial for refractory chronic cough (RCC): Positive data readouts presented at CHEST conference, enabling further clinical studies.
Phase I studies for IPF cough program: Completed drug-drug interaction study with no clinically meaningful changes in pharmacokinetics; respiratory safety study showed no safety signals.
TIDAL study: Progressing well with no safety signals; external safety review committee approved completion of enrollment.
Expansion into non-IPF interstitial lung diseases (ILD): Preparing for a study targeting non-IPF-ILD patients with lung fibrosis and chronic cough, doubling the market opportunity of IPF chronic cough.
Financial position: Raised $115 million in June 2025, with cash and investments totaling $195 million as of September 30, 2025, providing runway into 2028.
Operational planning: Preparing to initiate multiple trials in the first half of 2026, including Phase III for IPF chronic cough, non-IPF-ILD study, and RCC Phase IIb study.
Regulatory alignment: Engaging with FDA to align on Phase III program for IPF chronic cough and other NDA-enabling work.
Focus on chronic cough indications: Strategically advancing therapies for IPF chronic cough, non-IPF-ILD chronic cough, and RCC, addressing unmet needs in these areas.
Regulatory Compliance: The company faces challenges in aligning with FDA requirements for Phase III program design and other NDA-enabling work. This includes ensuring compliance with SOX 404(b) regulations, which has increased professional fees and personnel expenses.
Clinical Trial Execution: The company is managing multiple clinical trials simultaneously, including Phase III trials for IPF chronic cough and non-IPF-ILD, as well as a Phase IIb trial for RCC. This requires significant planning, coordination, and resource allocation to ensure successful execution.
Financial Sustainability: Although the company has a cash runway into 2028, its ability to fund multiple trials and ongoing studies is contingent on finalizing development plans for each indication. Any delays or cost overruns could impact financial stability.
Market Expansion: The company is targeting a broader market by including non-IPF-ILD patients, which doubles the market opportunity. However, this expansion requires additional regulatory approvals and clinical studies, increasing complexity and risk.
Safety and Efficacy: The company must address safety concerns, such as respiratory depression in IPF patients, as part of its clinical trials. Any adverse findings could delay or derail development plans.
Phase III program for chronic cough in IPF: The company plans to initiate the Phase III program for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) in the first half of next year. Preparations include aligning with the FDA on study design and protocol, as well as identifying sites and vendors for global studies.
Study for non-IPF interstitial lung diseases (ILD): Trevi is preparing to initiate a study for chronic cough in non-IPF interstitial lung diseases (ILD) after aligning with the FDA on the IPF pivotal program. This study will target a population of approximately 228,000 patients, potentially doubling the market opportunity of IPF chronic cough.
Phase IIb study for refractory chronic cough (RCC): The company plans to initiate a Phase IIb parallel arm dose-ranging study for refractory chronic cough (RCC) in the first half of next year. Preparations include drafting the protocol and identifying study sites.
Financial outlook and funding: Trevi has cash and investments totaling approximately $195 million as of September 30, 2025, providing a cash runway into 2028. This funding is expected to support 2 Phase III trials for IPF chronic cough, a Phase IIb/III trial for non-IPF-ILD chronic cough, a trial for RCC, and ongoing Phase I supportive studies.
The selected topic was not discussed during the call.
The earnings call presents a mixed sentiment. Financial performance is stable with a cash runway into 2028, but increased expenses and lack of clear guidance on critical studies raise concerns. The Q&A session highlights positive interest from the medical community and strategic planning, yet management's vague responses on potential risks and uncertainties, like orphan drug designation, dampen optimism. Given these factors, the stock price is likely to remain neutral in the short term, with no significant catalysts for a strong movement.
The earnings call summary presents a mixed picture: strong financial metrics and consistent trial progress are positive, but uncertainties in FDA meetings and potential DEA scheduling issues pose risks. The Q&A highlights no significant changes or new hurdles, maintaining a stable outlook. Without clear market cap data, the stock reaction is likely neutral.
The earnings call highlights several concerns: increased net loss due to R&D expenses, ongoing cash burn, and significant competition in the chronic cough market. Although the company has a substantial cash position, the high cash burn rate and financial risks are concerning. The Q&A session did not provide reassuring insights, with management lacking clarity on key trial metrics. Despite a completed $50 million offering, the financial outlook remains challenging. These factors suggest a negative sentiment towards the stock's short-term performance.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
